Feig et al. reported that the compound AMD3100, which targets CXCL12/CXCR4 signaling, could overcome antiCTLA4 and antiPD-1 treatment resistance by depleting carcinoma-associated fibroblasts in pancreatic cancer48. The gene discussed is CXCL12; the disease is carcinoma.